India, Feb. 21 -- Shares of Aerie Pharmaceuticals Inc. (AERI), a revenue-generating ophthalmic pharmaceutical company, are up more than 10%, following better-than-expected revenue for the fourth quarter and full-year ended December 31, 2019.
In the U.S., the Company markets Rocklatan and Rhopressa for the treatment of glaucoma or ocular hypertension.
The net product revenue from the two marketed products in the fourth quarter was $24.66 million compared to $14.45 million in the year-ago quarter. Wall Street analysts were expecting revenue of $19.46 million.
The full-year 2019 net product revenue soared to $69.89 million from $24.18 million in 2018, topping analysts' expectations of $64.73 million.
Rocklatan, under the brand name Rocland...